Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 2
224
Views
2
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Species and tissue differences in regorafenib glucuronidation

, &
Pages 129-133 | Received 02 Feb 2022, Accepted 16 Mar 2022, Published online: 29 Mar 2022
 

Abstract

  1. Regorafenib is glucuronidated mainly by uridine 5′-diphosphate glucuronosyltransferase (UGT) 1A9 in humans. UGT1A9 and its orthologues are expressed in the liver, small intestine, and kidney in humans and laboratory animals. The aim of this study was to reveal the species and tissue differences in regorafenib glucuronidation in the liver and extrahepatic tissues of humans and laboratory animals.

  2. Regorafenib glucuronidation was fitted to the Michaelis-Menten model in humans, monkeys, and mice using liver, kidney, and small intestine tissue. The hepatic results indicated monophasic kinetics in all species except rats, in which glucuronide could not be detected because rat Ugt1a9 is a pseudogene.

  3. The maximum velocity was higher in monkeys (3.41 pmol/min/mg) than in humans (1.21 pmol/min/mg), but was similar between humans and mice (1.11 pmol/min/mg). The maximum velocity in the kidney was higher than that in the liver in both humans and monkeys. Regorafenib glucuronide was not quantified in the kidneys of mice. Small intestinal regorafenib glucuronidation was not detected in any of the species. It is surmised that the degree of regorafenib glucuronidation is dependent on UGT1A9 expression levels.

  4. Our study clarified the species and tissue differences in regorafenib glucuronidation in the liver and extrahepatic tissues.

Acknowledgments

The authors thank Ms. Chiho Uehara for her technical assistance.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was financially supported by the Research Institute of Meijo University.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.